RecruitingPhase 2NCT04962867

NCCH2006/MK010 Trial (FORTUNE Trial)

Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)

Sponsor

National Cancer Center, Japan

Enrollment

75 participants

Start Date

Jun 15, 2021

Study Type

INTERVENTIONAL

Conditions

FGFR Gene Alterations Advanced or Recurrent Solid Tumors

Summary

This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called E7090 for people with advanced or recurrent solid tumors and fgfr gene alterations. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 20 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGE7090

140 mg of E7090 is orally administered once daily.

Locations(7)

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan, Japan

Kanagawa Cancer Center

Yokohama, Kanagawa, Japan

Tohoku University Hospital

Aoba-ku, Sendai, Miyagi, Japan

Kyushu University Hospital

Higashi-Ku, Fukuoka, Japan

Hokkaido University Hospital

Kita-Ku, Sapporo, Hokkaido, Japan

Okayama University Hospital

Okayama, Japan

Kyoto University Hospital

Sakyo-ku, Kyoto, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04962867

Related Trials

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT0699567746 locations

EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors

NCT065416392 locations

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT0691575316 locations